Open AccessP104 Branded infliximab still predominantly used over biosimilars in patients with IBD
Author(s) -
Price Lynn
Publication year - 2019
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000578488.30465.f4
Subject(s) - biosimilar , medicine , infliximab , audit , family medicine , brand names , pharmacy , alternative medicine , pharmacist , advertising , pathology , accounting , tumor necrosis factor alpha , business